Eli Lilly boosts production for obesity and diabetes drugs, reports mixed Q1 results. Expectations for supply growth in 2024 outlined. Insights into payor access and reimbursement strategies discussed.
Dana reported Q1 sales beat, affirming FY24 guidance amid efficiency gains. Company-wide efficiency improvements continue to offset the margin impact of inflation and spending on development for electric-vehicle products, Dana said.